[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"medication-nonadherence\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:medication-nonadherence":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100495559","mobile-video-directly-observed-therapy-dot-for-immunosuppression-medication-adherence-in-adolescent-heart-transplant-recipients-100495559",false,"NCT05732779","Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients","Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients: Enhancing Technological Innovation and Strengthening the Role of Small Businesses in Meeting Needs of Adolescent Organ Transplant","Inclusion Criteria:\n\n* Eligible participants are 10-21 years of age\n* Have received a heart transplant and are followed participating pediatric heart transplant centers\n* English-speaking or Spanish-speaking\n* Own a smart-phone or have access to the mobile app through other devices\n* Are willing to receive information through it\n* Have a MLVI score of greater than 2.0 over the last year\n\nExclusion Criteria:\n\n• Those with cognitive impairments will not be eligible for enrollment due to inability to provide informed assent","ALL","10 Years","21 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"NA","We will conduct a two-group randomized controlled trial to examine the eMocha DOT intervention with pediatric HT recipients.In this population, medication nonadherence remains a primary cause of late acute rejection (LAR) episodes, increased number of hospitalizations, graft failure, and patient mortality. Herein, we propose an innovative approach to promote medication adherence and improve patient and graft outcomes.",[27,28,29,30,31,32,33],"Heart Transplant Rejection","Immune Suppression","Pediatric Heart Transplant","Medication Nonadherence","Health Behavior","Remote Monitoring","Patient Engagement","RECRUITING","2026-02-24",{"date":37,"type":38},"2026-02-27","ACTUAL",{"date":40,"type":38},"2024-10-01",{"date":42,"type":21},"2027-05-01",{"name":44,"class":45},"University of Florida","OTHER",4,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":64,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":4},"100347527","studiio-diabetes-pilot-study-of-drug-insurance-to-improve-outcomes-of-diabetes-100347527","NCT03804905","STUDIIO-Diabetes Pilot: STUdy of Drug Insurance to Improve Outcomes of Diabetes","A Pilot Pragmatic Randomized Controlled Trial to Evaluate the Impact of Improving Access to Drugs on Type 2 Diabetes Care, Outcomes and Costs","Inclusion Criteria:\n\n* clinical diagnosis of type 2 diabetes record in family physician's electronic medical record\n* lack of medication insurance\n\nExclusion Criteria:\n\n\\-","25 Years","64 Years",{"count":57,"type":21},144,[24],"Canada is the only country with a universal health insurance system that does not provide coverage for prescription drugs to all residents. One-third of working-age Canadians have no insurance. Importantly, many of these uninsured patients already face other barriers to good health: low income, new immigrants, single mothers, etc. For these patients, taking prescription drugs - especially chronic disease treatments that may be required lifelong - can be difficult due to high costs. Patients skip doses, delay renewing prescriptions, or simply do not fill prescriptions recommended by their doctors, because they do not have insurance to cover the costs of prescriptions. Previous research by the study team has suggested that the lack of a universal drug insurance program for working-age Canadians affects the health and well-being of low-income people with diabetes. The goal of this research is to determine the clinical and economic impact of providing drug coverage for uninsured type 2 diabetics.",[61,62,63,30],"Type 2 Diabetes Mellitus","Medication Adherence","Medication Compliance",[61,63,65],"Medication Insurance","NOT_YET_RECRUITING","2024-12-19",{"date":69,"type":38},"2024-12-24",{"date":71,"type":21},"2026-01-01",{"date":73,"type":21},"2026-12-31",{"name":75,"class":45},"Sunnybrook Health Sciences Centre",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":84,"sex":16,"minAge":18,"maxAge":85,"enrollmentInfo":86,"targetDuration":4,"studyType":22,"phases":88,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":100},"100563275","adlip-human-coach-supported-digitalai-personal-health-assistant-to-improve-adherence-to-lipid-lowering-medication-100563275","NCT06614049","AdLip: Human Coach-supported Digital\u002FAI Personal Health Assistant to Improve Adherence to Lipid-Lowering Medication","AdLip: Use of Human Coach-supported Digital\u002FAI Personal Health Assistant to Improve Adherence to Lipid-Lowering Medications: a Multi-centre Randomised Controlled Trial","AdLip","Inclusion Criteria:\n\n* Between 21 to 84 years old\n* Prescribed statins with or without ezetimibe for hyperlipidaemia.\n* Medication non-adherence as defined by the \\"Extent to Non-adherence\\" sub-scale of the DOSE Non-Adherence Measure), with a score \\> 1 (range from 0-15)\n* Singapore residents (citizens, permanent residents, or long-term pass holders).\n* In possession of a smartphone or tablet with Android or iOS operating systems.\n* Have internet access on their mobile devices.\n\nExclusion Criteria:\n\n* Does not read or understand English. Current use of smartphone medication adherence app(s) that include statins.\n* Concurrent use of PCSK9 Inhibitors in addition to statins and\u002For ezetimibe\n* Participation in another study that uses medications that could affect lipid levels\n* Severe renal impairment defined as chronic kidney disease stage 4 and above.\n* Severe liver disease (Child-Pugh Class C)\n* Existing muscular-related complaints or diagnoses which may confound adverse event reporting\n* Uncorrected thyroid conditions, especially poorly-controlled hypothyroidism\n* Documented psychiatric diagnosis or history of mental illness or deemed as unable to give informed consent.\n* Currently pregnant, breastfeeding or expecting to get pregnant during the course of the study (1 year).\n* Guarded prognosis with expectant mortality within 12 months or less.",true,"84 Years",{"count":87,"type":21},450,[24],"Investigators hypothesize that the use of a human coach-supported digital\u002FAI personal health assistant (app) will improve adherence to cholesterol-lowering medications (statins with or without ezetimibe) among patients with hyperlipidaemia and suboptimal LDL-C control, when compared to standard care.",[91,30],"Hyperlipidemia",{"date":93,"type":38},"2024-10-03",{"date":95,"type":38},"2024-06-10",{"date":97,"type":21},"2026-02-14",{"name":99,"class":45},"National University of Singapore",2]